In neuroblastoma patients treated with 3F8 mouse anti-GD2, missing KIR ligand, lacking one or more HLA class I ligand for their inhibitory KIR, was associated with increased OS and progression-free survival (PFS), and in vitro unlicensed NK cells are spared from inhibition by cytokine-induced expression of self-HLA on tumor cells [70]. The gene discussed is KIR3DL1; the disease is neoplasm.